# A Study of Comparing Overall Improvement of Patients With Spondyloarthritis Treated With Jitongning Tablets and Placebo

> **NCT06000956** · PHASE3 · RECRUITING · sponsor: **Tasly Pharmaceutical Group Co., Ltd** · enrollment: 408 (estimated)

## Conditions studied

- Ankylosing Spondylitis

## Interventions

- **DRUG:** Jitongning tablets
- **DRUG:** a simulated agent of Jitongning tablets

## Key facts

- **NCT ID:** NCT06000956
- **Lead sponsor:** Tasly Pharmaceutical Group Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-11
- **Primary completion:** 2026-12-01
- **Final completion:** 2026-12-31
- **Target enrollment:** 408 (ESTIMATED)
- **Last updated:** 2024-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06000956

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06000956, "A Study of Comparing Overall Improvement of Patients With Spondyloarthritis Treated With Jitongning Tablets and Placebo". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06000956. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*